Pfizer’s New Phase 1b Results of Gene Therapy in Ambulatory Boys with Duchenne Muscular Dystrophy (DMD) Support Advancement into Pivotal Phase 3 Study
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
| Pfizer Inc. (NYSE: PFE) | Delayed: 29.85 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $29.85 | 52 Week High | $37.39 | |||
| Open | $29.85 | 52 Week Low | $28.25 | |||
| Day High | $29.85 | P/E | 18.09 | |||
| Day Low | $29.85 | EPS | $1.65 | |||
| Volume | 38,480 | |||||
